Home Non-Invasive Ventilation for COPD: How, Who and When?

Area of Science:

• Pulmonary Medicine
• Respiratory Care

Background:

• Chronic obstructive pulmonary disease (COPD) and chronic respiratory failure contribute to significant patient morbidity and mortality.
• While long-term home oxygen therapy is established, the role of home non-invasive ventilation (NIV) in chronic stable hypercapnic respiratory failure remains debated despite proven physiological benefits.

Purpose of the Study:

• To evaluate the clinical efficacy of home non-invasive ventilation (NIV) in patients with chronic stable hypercapnic respiratory failure.
• To identify patient phenotypes and optimal timing/delivery strategies for home NIV in COPD.

Main Methods:

• Review of recent clinical trial data and observational studies on home NIV and positive airway pressure (PAP) therapy in COPD.
• Emphasis on patient phenotyping, including degree of hypercapnia (PaCO2 >7kPa or 50mmHg) and exacerbator status (frequent vs. infrequent).
• Consideration of assessment timing (2-4 weeks post-acidosis recovery) and NIV titration for sleep-disordered breathing.

Main Results:

• Early trials had limitations, including marginally hypercapnic patients and suboptimal NIV delivery.
• Recent evidence supports home NIV for chronic hypercapnia and specific exacerbator phenotypes.
• Observational data suggest benefits of NIV or CPAP for COPD patients with or without obstructive sleep apnoea (OSA).

Conclusions:

• Home NIV may be clinically effective in selected COPD patients with persistent hypercapnia and specific exacerbator profiles.
• Optimizing NIV delivery, patient selection, and timing of assessment are crucial for successful outcomes.
• Positive airway pressure therapies, including NIV and CPAP, show potential for COPD patients with co-existing OSA.